TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01837147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-Based Physical Activity Promotion
Description: Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer Intervention
Description: Participants assigned to this group will receive a pedometer and be trained in its use.
Study: NCT04004507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate Ophthalmic Solution 1%
Description: Topical Sterile Ophthalmic Solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Description: Topical Sterile Ophthalmic Solution
Study: NCT06235164

Intervention type: DRUG
Intervention: immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab
Description: Drug: Sintilimab, Nivolumab, and Camrelizumab，One course will last 21 days.Given once every 3 weeks at a dose of 200 mg. Drug: nab-paclitaxel nab-paclitaxel one course will last 21 days#Given twice every 3 weeks at a dose of 125 mg/m2. Drug:oxaliplatin Oxaliplatin one course will last 21 days#Given once every 3 weeks at a dose of 130 mg/m2.~Drug:docetaxel docetaxel one course will last 21 days#Given once every 3 weeks at a dose of 40mg/m2.~Drug:fluorouracil fluorouracil one course will last 14 days#Given once every 2 weeks at a dose of 2800mg/m2.~Drug: Capecitabine Capecitabine was calculated according to body surface area every 3 weeks at a dose of 1000 mg/m2, P.O., bid, d1-d14 Drug: S1 S-1 was calculated according to body surface area, P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg everytime;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
Study: NCT03928561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active intense Pure Air XL air cleaner
Description: Cat allergen is nebulized in the EEC. When the concentration is stable, air cleaners are switched on. The number of air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of active air cleaners in the EEC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active intense Pure Air XL air cleaner
Description: Cat allergen is nebulized in the EEC. When the concentration is stable, air cleaners are switched on. The number of air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of active air cleaners in the EEC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Intense Pure Air XL air cleaner
Description: Cat allergen is nebulized in the EEC. When the concentration is stable, placebo air cleaners are switched on. The placebo effect is obtained thanks to the removal of air cleaners filters prior to the exposure. The number of placebo air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of placebo air cleaners in the EEC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Intense Pure Air XL air cleaner
Description: Cat allergen is nebulized in the EEC. When the concentration is stable, placebo air cleaners are switched on. The placebo effect is obtained thanks to the removal of air cleaners filters prior to the exposure. The number of placebo air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of placebo air cleaners in the EEC.
Study: NCT01079455

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosterone
Description: Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
Study: NCT00870272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400mcg misoprostol taken sublingually or buccally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400mcg misoprostol taken sublingually or buccally
Study: NCT00478972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study: NCT01079455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosterone
Description: Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosterone
Description: Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
Study: NCT00478972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for Rimonabant)
Description: Tablet, oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet and exercise
Description: Target daily caloric intake: Ideal body weight × 25 kcal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Description: Target daily caloric intake: Ideal body weight × 25 kcal
Study: NCT01270646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system
Description: Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.~Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping.
Study: NCT03809065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
Study: NCT02083250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic peripheral blood stem cell or bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell or bone marrow transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell or bone marrow transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT03327922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicryl absorbable suture
Description: Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicryl absorbable suture
Description: Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
Study: NCT02116972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Single 5 mL IA injection
Study: NCT03738579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Science Group
Description: TorrentX Wound Wash will be used for irrigation and then BlastX Wound Gel will be applied to the wound after debridement/irrigation during in-clinic visits. BlastX Wound Gel will be re-applied again during mid-week dressing change. Dressing used will be plain foam dressing from control group arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Foam Dressing will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antibacterial Control Group
Description: Foam Dressing AG will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
Study: NCT02116972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single 5 mL IA injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 16 mg
Description: Single 5 mL IA injection
Study: NCT01573208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom guides
Description: Symbios custom guides for TKA
Study: NCT00719732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSTOR
Description: Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
Study: NCT02092415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of a Junctional Tourniquet
Description: All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.
Study: NCT04267653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine
Description: treatment for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine
Description: treatment for 30 days
Study: NCT04024683

Intervention type: PROCEDURE
Intervention: Serratus block with ropivacaine 2mg/ml
Description: The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
Study: NCT02676349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFolfirinox
Description: oxaliplatin folinic acid irinotecan 5FU oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfirinox
Description: oxaliplatin folinic acid irinotecan 5FU oxaliplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: conformational external irradiation (50.4 Gy) + capecitabine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: 1 to 4 weeks after neoadjuvant treatment according to tumour response

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: 1 to 4 weeks after neoadjuvant treatment according to tumour response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
Study: NCT04267653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: treatment for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: treatment for 30 days
Study: NCT02949310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT02584790

Intervention type: DEVICE
Group type: OTHER
Intervention: Laryngoscope with NBI system
Description: All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
Study: NCT02542514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)
Study: NCT03750110

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: In addition to usual care, personalised feedback from the participants screening appointment will be provided;~* For participants with emphysema, an image of their own emphysematous lung compared to a library image of normal lung, or a section of their own non-emphysematous lung. Where emphysema is not present, library pictures showing normal and emphysematous lung will be used.~* For participants with coronary artery calcification, a cross sectional segment from their chest scan (either horizontal or vertical) showing the calcium compared to a library image of coronary arteries without calcification and/or a healthy section of the participant's own heart scan. Where coronary artery calcification is not present, library pictures showing normal and calcified coronary arteries will be provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Smoking cessation support in line with NICE PH48 guidelines
Study: NCT04099901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subjects will be treated with a daily dose of 300 mg anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
Study: NCT01924065

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion
Description: Electrical cardioversion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion
Description: Electrical cardioversion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Anticoagulant
Description: warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
Study: NCT03165981

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: ACIP Recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: ACIP Recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTaP
Description: ACIP Recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTaP
Description: ACIP Recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IIV
Description: ACIP Recommended vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IIV
Description: ACIP Recommended vaccine
Study: NCT04996849

Intervention type: OTHER
Intervention: Data Capture
Description: Data collected

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02299869

Intervention type: DEVICE
Group type: OTHER
Intervention: Azul (Competitor-control)
Description: contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Blue (CVI-test)
Description: contact lens
Study: NCT01245777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose
Description: 20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
Study: NCT04370236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INB03
Description: Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03
Study: NCT02898740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural exercise
Description: Exercise instruction and encouragement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Provision of general information about a variety of health topics
Study: NCT04210544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental dietary protein
Description: Breakfast intake consisted on a 250 g custard intake mixed with 20 g of the experimental protein accompanied by a glass with 50 mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein
Description: Breakfast intake consisted on a 250 g custard intake mixed with 20 g of casein accompanied by a glass with 50 mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Breakfast intake consisted on a 250 g custard intake mixed with 20 g of water accompanied by a glass with 50 mL water.
Study: NCT01968031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg
Description: Istradefylline 40 mg and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg
Description: Istradefylline 20 mg and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00563394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ofloxacin
Description: 400 mg twice a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSI-78
Description: 1%/2% topical cream twice a day for 14 days
Study: NCT02218216

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI Diagnostic
Description: Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Diagnostic
Description: Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
Study: NCT02921516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: N'ap Grandi
Description: Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: N'ap Grandi - A
Description: Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Promotion - A
Description: Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
Study: NCT02151149

Intervention type: DRUG
Group type: OTHER
Intervention: nab-paclitaxel
Study: NCT04370236

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive up to two once per week subcutaneous injections of Placebo
Study: NCT02151149

Intervention type: DRUG
Group type: OTHER
Intervention: nab-paclitaxel

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Study: NCT02893540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: we are going to compare two maintenance treatment models with capecitabine in this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: we are going to compare two maintenance treatment models with capecitabine in this study
Study: NCT02151149

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Study: NCT02233751

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate auto-injector
Description: Randomization then administration of combination product study medication according to group assignment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate auto-injector
Description: Randomization then administration of combination product study medication according to group assignment
Study: NCT03345615

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 30-day ambulatory cardiac event monitor
Description: SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
Study: NCT02484508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guli capsule
Description: Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kangguzengsheng capsule
Description: Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
Study: NCT02627001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuMask Intraoral Airway Device
Description: NuMask Intraoral Airway Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bag Valve Mask
Description: Conventional bag valve mask
Study: NCT04537520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerecis Omega3 Wound
Description: Treatment of the wound with Kerecis Omega3 Wounds matrices
Study: NCT03710551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Infant Formula
Description: Standard bovine milk-based infant formula, fed ad libitum
Study: NCT02002130

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo GABA and Placebo GAD-alum
Description: Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GABA and Placebo GAD-alum
Description: Oral Active GABA with Placebo GAD-alum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Oral GABA and Active GAD-alum injection
Description: Active Oral GABA and Active GAD-alum injection
Study: NCT03914898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse led intervention group
Description: This program is based on cognitive restructuring tecniques.